Biotechnology

Alligator Bioscience Appoints Johan Giléus as CEO – Søren Bregenholt To Step Down at Year-End

October 4, 2026 10:50 AM

Alligator Bioscience (Nasdaq Stockholm:ATORX), a biotechnology company whose principal value driver is a financial interest in the HER2-targeting antibody programme HLX22, today announced that the Board of Directors has appointed Johan Giléus as Alligator's new Chief Executive Officer (CEO), effective 1 January 2027. The appointment follows Alligator's strategic refocusing towards its financial interest in HLX22, as announced on 23 July 2026....

Read more

American Gene Technologies to Present at the NIBA 153rd Investment Conference in Fort Lauderdale

October 2, 2026 1:00 PM

American Gene Technologies ("AGT"), a clinical-stage biotech developing AGT103-T - the only program to demonstrate elimination of the HIV viral reservoir in humans - will present at the National Investment Banking Association (NIBA) 153rd Investment Conference on October 6-7, 2026. AGT is raising $55 million to fund its Phase 2 trial of this one-time, gene-modified T-cell therapy targeting a functional cure for HIV in a $40 billion annual...

Read more

FluoGuide Enters Collaboration with Leica Microsystems, a World Leading Medical Technology Company

October 2, 2026 12:50 PM

FluoGuide A/S (STO:FLUO) FluoGuide A/S ("FluoGuide" or the "Company"), a biotech company specializing in precision cancer surgery, announces a collaboration with Leica, a world leading medical technology company. FluoGuide aims to improve outcomes for patients with cancer by enabling more precise oncology surgery. Our lead product, FG001, has been clinically proven to light up cancer and guide surgeons in performing more precise surgeries. FG001...

Read more

enVVeno Medical's First-in-Class enVVe System to Be Featured at The VEINS 2026 Innovation Summit as Company Advances Toward U.S. Pivotal Trial

October 2, 2026 8:44 AM

enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno Medical" or the "Company"), today announced that the Company will present its investigational enVVe® System at The VEINS 2026 in Las Vegas, Nevada. The presentation will take place on Sunday, October 4, 2026 at the Blue Sky Breakfast consisting of a gathering of specialists focused on advances in venous and vascular disease. The presentation will be followed by panel discussion and Q&A session....

Read more

RMTG Expands Peptide Education Platform With ISSCA Peptide Certification 2.0 and New Physician Reference Guides

October 1, 2026 7:01 AM

Oct 1, 2026, Regenerative Medical Technology Group Inc. (the "Company" or "RMTG") (OTCID:RMTG), a regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group, today announced the launch of Peptide Certification 2.0 through its International Society for Stem Cell Applications (ISSCA) division, an expansion of the organization's peptide-medicine education and certification program. The upgraded program...

Read more

Faron Announces First Patient Dosed in BLAZE Investigator-Initiated Trial

October 1, 2026 2:15 AM

Faron Pharmaceuticals Ltd. (HEL:FARON)(LSE:FARN) , a global, clinical-stage biopharmaceutical company focused on creating innovative cancer treatments that leverage the patient's own immune system, today announces that the first patient has been dosed in the Phase 1/2 BLAZE investigator-initiated trial. The trial evaluates Faron's lead asset, bexmarilimab, in combination with the widely used anti-PD-1 checkpoint inhibitor nivolumab (OPDIVO®) in...

Read more

PharmaNest and Mediar Therapeutics Collaborate to Quantify ECM and Fibrosis Remodeling in the EncompaSSc Phase 2 Trial of MTX-474 in Diffuse Cutaneous Systemic Sclerosis

September 30, 2026 1:00 PM

PharmaNest, Inc. an AI-enabled digital pathology company specializing in the quantitative and spatial characterization of fibrosis and Mediar Therapeutics, Inc., a clinical-stage biotechnology company pioneering first-in-class therapies to halt and reverse fibrosis, today announced a collaboration to integrate advanced digital pathology into Mediar's ongoing EncompaSSc Phase 2 clinical trial of MTX-474 in patients with diffuse cutaneous systemic...

Read more

Announcement From the Extra General Meeting in Biovica International AB

September 30, 2026 9:20 AM

Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - The extra general meeting of Biovica International AB ("Biovica" or the "Company") was held today on 30 September 2026 and the following resolutions were passed by the meeting. Approval of the board of directors' resolution on a rights issue of shares The extra general meeting resolved to approve the board of directors' resolution on 9 September 2026 on a rights issue of a maximum of...

Read more

Increase in Number of Shares and Votes in Vicore Pharma

September 30, 2026 3:20 AM

Vicore Pharma Holding AB (STO:VICO)(NASDAQ:VCRE), unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists, today announced that the number of Vicore shares and votes has increased following the exercise of warrants with subsequent delivery of shares to participants in the incentive programs Board LTIP 2023, Board LTIP 2024 and Board RSU 2025. The shares were issued through the exercise of 117,737 share...

Read more

Faron Pharmaceuticals Ltd: Convertible Bond Amortization Payment Deferred by Mutual Agreement With HCM

September 30, 2026 2:20 AM

Faron Pharmaceuticals (HEL:FARON)(LSE:FARN), a clinical-stage biopharmaceutical company developing novel immunotherapies, announces that the Company and Heights Capital Management, Inc. ("HCM") have mutually agreed to defer the amortisation payment of the First and Second Tranche Bonds (as defined below) scheduled for 2 October 2026. The Company announced on 3 April 2025 that it had entered into a convertible bond arrangement for up to EUR 35...

Read more

Alligator Bioscience Carries Out a Directed Issue of Warrants to Fenja Capital in Connection with The Completed Rights Issue

September 29, 2026 6:00 AM

Alligator Bioscience (STO:ATORX) - The Board of Directors of Alligator Bioscience AB ("Alligator Bioscience" or the "Company"), has today, based on the authorization granted by the extraordinary general meeting on 26 August 2026, resolved on a directed issue of 187,795,097 warrants series 2026/2031 to Fenja Capital II A/S ("Fenja Capital"). The issue constitutes part of the renegotiation of the outstanding loan from Fenja Capital which was...

Read more

Immortal Dragons Backs Renewal Bio to Grow Patient-Matched Cell Platform

September 28, 2026 9:40 PM

Immortal Dragons, the $40 million purpose-driven longevity fund, today announced its strategic investment in Renewal Bio, an Israeli regenerative medicine company developing patient-matched human cells for transplantation. Renewal Bio was founded in 2022 as a spinout of the Weizmann Institute of Science. It is building its Stembroid™ platform to produce cells by harnessing the same developmental program that forms them naturally in the body....

Read more

Lifeloc Technologies to Participate in Lytham Partners Fall 2026 Investor Conference

September 28, 2026 12:50 PM

Lifeloc Technologies, Inc. (OTCID:LCTC), a global leader in the development and manufacturing of breath alcohol and drug testing devices, will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2026 Investor Conference, taking place virtually on September 29-30, 2026. In addition to background on the current Lifeloc business in breath alcohol testing, management will discuss the status...

Read more

IGC Pharma Completes Enrollment in Phase 2 CALMA Alzheimer's Trial; Topline Results Expected Q4 2026

September 28, 2026 8:00 AM

IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company") today announced it has completed enrollment in its CALMA Phase 2 trial evaluating lead asset, IGC-AD1, for agitation in Alzheimer's dementia. Enrollment complete; final participant dosing expected to conclude in early November; topline results expected Q4 2026 CALMA achieved target enrollment with 168 participants randomized, including planned over-enrollment designed to strengthen...

Read more

NGD Infection Prevention Announces Launch of Transmission Detection at Sheba Medical Center in Israel

September 24, 2026 6:15 PM

NGD Infection Prevention (NGD) today announces that its automated WGS sample preparation and bioinformatic system is fully operational at Sheba Medical Center in Israel, the largest medical center in the Middle East, and is now enabling the real-time detection of the transmission of infection, for use by Sheba's Infection Prevention and Control (IPC) team in guiding interventions to prevent the spread of bacterial infection. This is NGD's first...

Read more

Synexis, LLC and Patterson Veterinary Collaborate to offer DHP(R) Technology to Animal Health Professionals Nationwide

September 24, 2026 9:20 AM

Synexis®, LLC, the leader in touchless, continuous pathogen control technology, today announced a strategic collaboration with Patterson Veterinary to expand access to Synexis DHP® technology for veterinary and animal health professionals nationwide. This collaboration reflects a growing industry focus on preparedness and the need for more continuous approaches to pathogen management in indoor animal care settings. Emerging research continues to...

Read more

NGD Infection Prevention Announces Launch of Transmission Detection at Sheba Medical Center in Israel

September 23, 2026 3:50 PM

NGD Infection Prevention (NGD) today announces that its automated WGS sample preparation and bioinformatic system is fully operational at Sheba Medical Center in Israel, the largest medical center in the Middle East, and is now enabling the real-time detection of the transmission of infection, for use by Sheba's Infection Prevention and Control (IPC) team in guiding interventions to prevent the spread of bacterial infection. This is NGD's first...

Read more

Microbix Presenting at Muskoka Capital Event

September 23, 2026 7:00 AM

Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF)(Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it will be presenting to investors at the Muskoka Capital Event, organized by Capital Event Management Ltd. and being hosted at the JW Marriott Rosseau Muskoka, in Minett, Ontario, September 25 to 27, 2025. Microbix's CEO, Cameron Groome, and Director of Product Management, Pavel Zhelev, will undertake a series of 18...

Read more

Biovica Receives First Work Order Under New Master Services Agreement for Phase 1 Oncology Study

September 22, 2026 2:45 AM

Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, a company specializing in blood-based cancer monitoring, today announces that it has received the first work order under its recently signed Master Services Agreement with an operating subsidiary of a U.S.-based biotechnology company developing next-generation precision medicines for cancer. The work order, valued at approximately USD 85,000, covers DiviTum® TKa testing in a...

Read more

AI Maverick Intel Appoints Dr. Wayne Young to Board as Company Advances HEAL Access Strategy with Corporate Update

September 21, 2026 2:40 PM

AI Maverick Intel, Inc. ("AIMV" or the "Company") (OTC PINK:AIMV) today announced the appointment of Dr. Wayne Young to its Board of Directors as the Company advances its definitive agreement to acquire HEAL Access Canada Inc. AIMV also announced the settlement and mutual rescission of its August 2024 transaction with Stronghold Media Group Corp. as part of the Company's corporate transition. Dr. Wayne Young Appointed to Board of Directors AIMV...

Read more